EUVIMEDEUVIMED entdecken
Crossref

Biopsy-proven stromal fibrosis: what is the appropriate management approach?

Prasaanthan Gopee-Ramanan, Sareh Keshavarzi, Supriya Kulkarni, Allison Grant, Frederick Au, Sandeep Ghai, Vivianne Freitas

Breast Communications · 2025

DOI: 10.21037/bc-25-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Communications, 2025. Verfasst von Prasaanthan Gopee-Ramanan und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Stromal fibrosis is a common benign finding in breast biopsies that can mimic carcinoma and occasionally coexist with malignancy. The key clinical question is whether biopsy-proven stromal fibrosis without atypia warrants surgical excision or can be safely managed with imaging surveillance. The purpose is to assess the upgrade rate of biopsy-proven stromal fibrosis without associated atypia and determine the most appropriate management approach for these patients.

Methods

A retrospective review of imaging-guided breast biopsies performed between 2014 and 2019 in a tertiary center was conducted under research ethics board (REB) approval. Patients with biopsy-proven stromal fibrosis without atypia were identified. The upgrade rate to malignancy and the imaging characteristics of upgraded cases following surgical excision were recorded. Final diagnoses were confirmed by surgical histopathology or, in cases without surgery, by an uneventful clinical and radiological follow-up of at least 2 years. Predictors of malignancy were evaluated using one-way analysis of variance (ANOVA) for normally distributed variables or the Kruskal-Wallis test for non-normally distributed variables. Categorical variables are compared in three groups by the Chi-squared test.

Results

Among 9,814 consecutive imaging-guided breast biopsies performed during the study period, 334 cases (4.8%) in 334 patients met the inclusion criteria, comprising the study cohort. The median patient age was 52 years. Of these, 4 cases (1.2%) were upgraded to malignancy within 2 years of follow-up. Older age (>50 years) was significantly associated with an upgrade to malignancy (P

Zitieren

APA

Gopee-Ramanan, P., Keshavarzi, S., Kulkarni, S., Grant, A., Au, F., Ghai, S., & Freitas, V. (2025). Biopsy-proven stromal fibrosis: what is the appropriate management approach?. Breast Communications. https://doi.org/10.21037/bc-25-9

Vancouver

Gopee-Ramanan P, Keshavarzi S, Kulkarni S, Grant A, Au F, Ghai S, et al. Biopsy-proven stromal fibrosis: what is the appropriate management approach?. Breast Communications. 2025. doi:10.21037/bc-25-9

BibTeX
@article{GopeeRamanan2025,
  author = {Gopee-Ramanan, Prasaanthan and Keshavarzi, Sareh and Kulkarni, Supriya and Grant, Allison and Au, Frederick and Ghai, Sandeep and Freitas, Vivianne},
  title = {Biopsy-proven stromal fibrosis: what is the appropriate management approach?},
  journal = {Breast Communications},
  year = {2025},
  doi = {10.21037/bc-25-9}
}
Kostenlos starten →